

HU:GGPAPPPAPPPPPPPPPPPSFIXQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAG MO:GGPAPPPAPPPPPPPPPPPSFIXQEPSWGGAEPHEEQCLSAFTLHFSGQFTGTAG

HU:ACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPS MO:ACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPTIRNQGYSTVTFDGAPS

HU: YGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTG MO: YGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTG

HU: SQALLLRTPYSSDNLYCMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTE MO: SQALLLRTPYSSDNLYCMTSQLECMTWNQMNLGATLKGMAAGSSSSVKWTE

HU: GQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSAS MO: GQSNHGIGYESDNHTAPILCGAQYRIHTHGVFRGIQDVRRVSGVAPTLVRSAS

HU: ETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSR MO: ETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSR

HU: SDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCR MO: SDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCR

HU: WPSCQKXFARSDELVRHENMHQRNMTKLQLAL MO: WHSCQKXFARSDELVRHENMHQRNMTKLHVAL



FIG. 2




FIG. 3






FIG. 4









FIG. 5A-5C





B Vaccine B stimulated line




FIG. 6A and 6B





FIG. 7A-7D

5		15				35				55				75
MGSDVRD	LNALL AAAAA	PAVPS AAAAA	LGGGG	GCAL	PVSGA AA	aqwap Aaaa.	VLDFA	PPGAS AA	AYGSL Aaaaa	GGPAP AAAAA	PPAPP	PPPPP	PPHSF	IKQE
					RR	RR								
• • • • • • • • • • • • • • • • • • • •	• • • •				• • • • •	• • • • •	• • • • •	• • • • •	• • • • •	• • • • •	• • • • •	• • • • •	• • • • •	• • • •
														• • • •
80 PSWGGAE	85 PHEFO	90 CLSAF	95 TVHF9	100 GOETO	105 STAGA	110 CRYG2	115 56000	120	125	130	135	140	145	
• • • • • • •		AA	Α	AA	AA				AA	A	AAA	AAA		-
• • • • • • • • • • • • • • • • • • • •	• • • • •	• • • • •	• • • • •		RRRR.	••••	• • • • •		Ri	RRRR.		• • • • •	• • • • •	
•••••					 		• • • • •	••••		 	<i>.</i>			• • • •
TVTFDGT	PSYGH	165 TPSHH	170 AAQFP	1/5 NHSFI	KHEDP!	MGQQG:	190 SLGEO	195 OYSVP	200 PPVYG	205 CHTPT	210 DSCTG	215 SOALL	220	225 SDN
		A	AAAA.							AAAAA	A			AA
• • • • • • • • • • • • • • • • • • • •		R	RRR		 	 	• • • • •	• • • • •	• • • • •	• • • • •		יייייייייייייייייייייייייייייייייייייי	יחחחחח	
• • • • • • •						• • • • •		• • • • •						
230	235	240	245	250	255	260	265	270	275	280	285	290	295	300
LYCMTSQ	LECMT	WNQMN	LGATL	KGVA	AGSSS	SVKWT:	EGQSNI	HSTGY	ESDNH	TPIL	CGAQY	RIHTHO	GVFRG	ODV
AAAAAAA	A		AA	A.AAA RRRRE	A	 . वववः		• • • • •	• • • • •	• • • • •		AA	AAAAA	AAA
DDDCDD.			D	וסססס	וססססכ	o				<i>.</i>		<i>.</i>	. 	
• • • • • • •	• • • • •		• • • • •	• • • • •		• • • • •	• • • • •	• • • • •	• • • • •			ddddd		
		315			330	335	340	345	350	355	360	365	370	375
RRVPGVA AAAAA	PTLVR:	SASET	SEKRP a	FMCA:	PGCNI	KRYFK:	LSHLQN	1HSRK	ITGEK:	SXQCDI	FKDCE	RRFSRS	SDQLKE	HQR
RRR	RR					RRRR.		. .						
	DDDDDI	D					· · · · · ·	· • • • •	· • • • •					
380	385 :	390	395	400	405	410	415	420	425	430	435	440	445	450
RHTGVKP		. AAAA	. AAAA	AA.		AAA		A#	λ Α	AAAA	AAAA.	. AAA.		
• • • • • • •									RRRF	RRR	RR			
• • • • • • •														• •

5	10	15	20	25	30	35	40	45	50	55	60	65	70	75
MGSDVF														
• • • • •														
• • • • • •														
												140		
PSWGGA														
• • • • •														
• • • • • •														
• • • • • •														
• • • • • •	• • • • •	• • • • •	• • • • •			• • • • •	• • • • •	• • • • •	• • • • •		• • • • •	• • • • •	• • • • •	• • • •
166	1.50	1.00	170	176	100	105	100	100	200	225	010	215	222	205
TVTFDG														
									• • • • •					• • • •
230	235	240	245	250	255	260	265	270	275	280	285	290	295	300
LYQMTS														
AAAAA														
DDDDDD														
				. 								ddddd		
												365		
RRVSGV	APTL	/RSAS	ETSEKF	SPEMC2	Z PGCN	KRYF3	ilshlq	MHSRK	CHTGEK	SAĞCD	FKDCE	RRFSR	SDQLK	RHQR
AAAAA .														
RF														
• • • • • •				• • • • •	• • • • •		• • • • •		• • • • •	• • • • •	• • • • •	• • • • •	• • • • •	• • • •
200	385	200	205	400	105	110	=	120	425	430	435	440		450
380 RHTGVK														
• • • • • •	• • • • •							• • • • •	מספ	המאמה. ספ פ	AAAA.			• • •
• • • • • • • • • • • • • • • • • • •														
	- · · · ·						- • • • •		• • • • •					•••






FIG. 9A and 9B

12




FIG. 10A

//




FIG. 10B

1.




FIG. 10C




FIG. 10D

12




FIG. 11A and 11B





FIG. 12A and 12B

le.








FIG. 13A-13C



F19. 14



F19.15




Fig. 16

10




Fig. 17

TABLE 1: Characteristics of Recombinant WT1 Proteins Used for Serological Analysis

Molecular Weight 85kDa 60kDa	50kDa
WT1 Amino Acid Position aa 1-449 aa 1-249	aa 267-449
Recombinant Protein Ra12-WT1 full length fusion protein TRX-WT1 N-terminus fusion protein	WII C-terminus protein
Name WT1/full-length WT1/N-terminus	W I I/C-terminus

F. G. 8

TABLE 2: WT1 Specific Serum Antibodies in Patients with AML and CML.

WT1/C-terminus	1/96 (1%)	2/63 (3%)	3/81 (3%)
WT1/N-terminus	1/96 (1%)	16/63 (25%)	12/81 (15%)
		14/63 (22%)	15/81 (19%)
i i	Normal Individuals (n=96)	AML Patients (n=63)	CML Patients (n=81)

F19. 19

2/2